Cellectis SA Outlines 2026 Strategy with Focus on Advancing Pivotal Phase 2 CAR-T Trials, Presenting Key Clinical Data, and Expanding Strategic Partnerships

Reuters01-09
Cellectis SA Outlines 2026 <a href="https://laohu8.com/S/MSTR">Strategy</a> with Focus on Advancing Pivotal Phase 2 CAR-T Trials, Presenting Key Clinical Data, and Expanding Strategic Partnerships

Cellectis SA has outlined its strategic priorities for 2026, focusing on advancing its allogeneic CAR-T cell therapy pipeline and expanding strategic partnerships. Key plans include executing the pivotal Phase 2 BALLI-01 trial for lasme-cel in acute lymphoblastic leukemia $(ALL)$, with interim data expected in the fourth quarter of 2026, and presenting the full Phase 1 data of the NATHALI-01 trial for eti-cel in non-Hodgkin lymphoma (NHL). Patient enrollment has begun for a cohort evaluating low-dose interleukin-2 (IL-2) support in NHL, with full Phase 1 dataset results anticipated in late 2026. Cellectis will continue its collaboration with AstraZeneca to develop up to 10 novel cell and gene therapy products and remains eligible for milestones and royalties from partnerships with Servier/Allogene and Iovance. The company projects its current cash resources will fund operations into the second half of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellectis SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9622564-en) on January 08, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment